MGNX · Macrogenics Inc

Track MGNX — free

$3.58 -0.02 (-0.56%) At close · Oct 2

Russell 2000 member Rebalance outlook locked

Market Cap

$238.24M

63.70M

Volume · Oct 2 980.53K Avg daily vol (3M) 633.16K

Up next

Latest filing: 10-Q

filed Aug 14, 2026

Q2 2024 earnings call transcript

call held Aug 6, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$183.05M

Trailing 12 months

Net income (TTM)

−$14.59M

Trailing 12 months

Revenue growth YoY

+378.0%

Year over year

Operating margin

-18.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-27.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$113.91M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.7%

Year over year · more shares

Price change (1Y)

+109.4%

Trailing year

Short interest

11.0%

Latest settlement · 15.7 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Neutral Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg +10%

above

Price vs 50-day avg −11%

below

RSI (14) 38

neutral

MACD trend Negative

52-week position 64%

mid-range

Momentum

relative strength

Neutral

1-month return −16%

trailing

6-month return +3%

trailing

YTD return +122%

this year

Relative strength −9%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

+12% holders QoQ · +38 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

11.04% of float · ▼ -1.3% MoM · 15.7 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

122 holders — mid 3-yr range

Squeeze score 60

elevated · 0–100

Fundamentals

Poor

Revenue growth −0%

Y/Y

EPS growth −10%

Y/Y

Free cash flow $-83.0M

Quant / Vol

risk profile

Very High

Volatility 86%

annualized · 1-yr

Max drawdown −34%

past year

ATR 6.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

2 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+10% Bullish

Price vs 50-day avg

−11% Bearish

RSI (14)

38 Neutral

MACD trend

Negative Bearish

52-week position

64% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

+12% holders QoQ · +38 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

11.04% of float · ▼ -1.3% MoM · 15.7 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

122 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $4 · 64% Range high $5

vs 200-day avg +10% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Income from operations of the CDMO Operations	$3M	the three months ended June 30, 2026 filing	—
Pretax net gain on sale of CDMO Operations	$86.1M	the three months ended June 30, 2026 filing	—
Pro forma cash, cash equivalents and marketable securities	$327M	Q2 2026	—
Shares of common stock outstanding	63,645,711	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MGNX Macrogenics Inc this stock	$238.24M	+122.4%	-0.3%	—	11.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

122

% held: 76.6%
Net QoQ: +5.4M sh
Top holder: ARMISTICE CAPITAL, LLC

Held Float

View

Held by Funds

Fund positions

116

View

Short & Settlement

Short Interest Falling

Shares short

7.0M

Days to cover: 15.7d
Change: -92.5K sh

View

Short Volume

Short vol %

38%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

256

Value: $1.0K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

32.3%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$149.5M

Net income (FY): $-74.6M
EPS diluted: $-1.18

View

Filings

SEC Filings

Latest

8-K/A

Filed: Sep 3, 2026
This year: 17

View

Proposed Sales

Value

$798.8K

Shares: 51.4K
Filed: Apr 4, 2024

View

Earnings & Events

Webcasts

Last webcast

May 20, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
MGNX	-4.3%	-15.8%	+3.2%	-7.3%	+122.4%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-4.1%	-15.3%	-9.0%	-8.2%	+109.5%

Key facts CIK 1125345 CUSIP 556099109 13F (30d) 2 filings 2 filers Visit website Investor relations

MGNX · Macrogenics Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance